Drug
S 217622
S 217622: highest development phase Phase 3, developed by Shionogi. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| S-217622 NCT05305547 | Phase 3 | SARS-CoV-2 Infection |
| S-217622 NCT05897541 | Phase 3 | SARS-CoV-2 Infection |
| S-217622 NCT05409911 | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow S 217622 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.